Selank
Also called TP-7; Thr-Lys-Pro-Arg-Pro-Gly-Pro
A seven-amino-acid peptide studied mainly for anxiety in small Russian trials. It is not an FDA-approved anxiety medicine, and claims of "no side effects" or "non-addictive" go beyond the evidence.
Overview
What it is
A synthetic analogue of tuftsin, a natural immune peptide, with three amino acids added.
How it works
In rat brain tissue, it produced gene-expression patterns overlapping with GABA, the main calming neurotransmitter. In human-derived cells, Selank alone did not change those genes. It also slows enzymes that break down enkephalins in serum samples.
What the research shows
Small Russian studies compared Selank with benzodiazepines (medazepam, phenazepam) in anxiety disorders and reported similar effects. Large placebo-controlled trials are lacking.
Studied for
- Generalized anxiety and neurastheniasmall human studies
- GABA-related gene expressionrats, cells
Safety and regulatory status
Safety and side effects
Long-term safety is incomplete. FDA flags immune and impurity concerns for compounded Selank acetate. No reliable interaction data with antidepressants, sleep medicines or alcohol. Never stop a prescribed benzodiazepine abruptly; tapering needs medical supervision.
Regulatory status
Not FDA approved. On FDA's list of compounding substances with potential safety risks.
Mixing and dosing reference
Reference information only. Read before using this section.
Selank Dosage (10 mg Vial) Protocol
- Vial
- 10 mg Selank
- Add diluent
- 5 mL or 10 mL measured nasal solution
- Concentration
- 2 mg/mL (5 mL) or 1 mg/mL (10 mL)
- 1 unit (U-100)
- 200 mcg (5 mL) or 100 mcg (10 mL) per 0.10 mL spray
- Route
- Intranasal
Selank 10 mg Nasal Spray Dosage Calculations
| Measured Final Volume | Vehicle Added After Transfer | Final Concentration | Per Verified 0.10 mL actuation |
|---|---|---|---|
| 5.0 mL | About 2.0 mL | 2,000 mcg/mL | 200 mcg50 nominal actuations |
| 10.0 mL | About 7.0 mL | 1,000 mcg/mL | 100 mcg100 nominal actuations |
| 6.67 mL (registered-product concentration reference) | About 3.67 mL | 1,500 mcg/mL | 150 mcg66.7 nominal actuations |
Published Intranasal Research Schedule
| Period | Amount | actuation Volume | Frequency |
|---|---|---|---|
| Days 1–14 | 300 mcg per administration (900 mcg/day) | 0.20 mL at 1.5 mg/mL (2 verified 0.10 mL actuations) | 3 times daily |
Mathematical Actuator Equivalents
| Literature Amount | 5 mL Option200 mcg each actuation | 10 mL Option100 mcg each actuation |
|---|---|---|
| 300 mcg | 1.5 theoretical actuations | 3 actuations |
| 900 mcg | 4.5 theoretical actuations | 9 actuations |
| 2,700 mcg | 13.5 theoretical actuations | 27 actuations |
Published Intranasal Selank Clinical Studies
| Source | Research Context | Published Intranasal Amount and Formulation |
|---|---|---|
| Zozulia et al., 2008 | 62 adults with GAD or neurasthenia | Selank 0.15% nasal drops at 2.7 mg per day, reported as 36 drops divided across three administrations, with outcomes followed through day 14. |
| Syunyakov et al., 2012 | 20 adults with GAD | 2,700 mcg per day intranasally. The pharmaco-EEG analysis also examined a single 900 mcg exposure. |
| Panikratova et al., 2020 | Healthy-volunteer functional connectivity study | One intranasal exposure using 0.15% Selank solution, 60 microliters per nostril, described as a 0.2 mg total amount. |
Core Formula
| Verified Actuator Output | 5 mL Option2,000 mcg/mL | 10 mL Option1,000 mcg/mL |
|---|---|---|
| 0.05 mL | 100 mcg | 50 mcg |
| 0.10 mL | 200 mcg | 100 mcg |
| 0.13 mL | 260 mcg | 130 mcg |
How to mix
- Add a small measured amount of sterile diluent to the vial and swirl gently until dissolved.
- Transfer the solution to a clean nasal spray bottle.
- Bring it to an exact measured final volume of 5 mL or 10 mL (see the chart above).
- Prime the pump and confirm it delivers 0.10 mL per full spray before use.
Important notes
- Small measurement and device details can materially change the amount delivered per actuation.
- Use a measured final volume, not the bottle capacity mark alone.
- Verify that the actuator releases 0.10 mL per full stroke before applying the main table.
- Prime and reprime exactly as specified for the pump, then record those actuations.
- Keep the bottle upright and use a complete, consistent stroke for each recorded actuation.
- Treat the theoretical 50 or 100 actuations as nominal counts because priming and residual hold-up consume part of the volume.
- A 10 mg vial contains 10,000 mcg total. Calculate the complete peptide requirement before modeling any multi-day published protocol.
- Use a validated laboratory handling and stability plan for any custom multidose preparation.
Protocol source: PeptideDosages.com
Common questions
Does Selank help anxiety?
Small studies are encouraging but not conclusive. Established treatments include CBT and medication.
Is Selank non-addictive?
The evidence does not support a blanket guarantee.
Is it the same as Semax?
No. They are different peptides.
Found in these blends
Related in Brain and Cognitive Health
Sources and further reading (6)
- Zozulia AA, et al. Selank in generalized anxiety disorders and neurasthenia, 2008.
- Medvedev VE, et al. Selank vs phenazepam in anxiety disorders, 2014.
- Volkova A, et al. Selank and GABAergic gene expression. Front Pharmacol, 2016.
- FDA. Bulk drug substances that may present significant safety risks: Selank acetate.
- NIMH. Generalized anxiety disorder.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).
Laboratory research material: Selank Research Use Only